C5a receptor

I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Tuesday, October 27, 2020
Branches of biology, Cell biology, Phagocytes, Immune system, Myeloid-derived suppressor cell, Tumor microenvironment, Cancer immunotherapy, C5a receptor, Neutrophil, Macrophage, Complement component 5a, Innate lymphoid cell

TJ210/MOR210 is a novel human antibody directed against C5aR derived from MorphoSys's HuCAL Platinum technology.

Key Points: 
  • TJ210/MOR210 is a novel human antibody directed against C5aR derived from MorphoSys's HuCAL Platinum technology.
  • C5aR, the receptor of the complement factor C5a, is investigated as a potential new drug target in the field of immuno-oncology and autoimmune diseases.
  • Tumors have been shown to produce high amounts of C5a, which, by recruiting and activating myeloid-derived suppressor cells (MDSCs), M2 macrophages and neutrophils, is assumed to contribute to an immune-suppressive pro-tumorigenic microenvironment.
  • TJ210/MOR210 is intended to block the interaction between C5a and its receptor, thereby potentially neutralizing the immune suppressive function and enabling immune cells to attack the tumor.

DGAP-News: MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer

Retrieved on: 
Thursday, September 17, 2020
MorphoSys, C5a receptor, MOR210/TJ210, I-Mab

MOR210/TJ210 is thought to block the interaction between C5a and C5aR1 by binding to C5aR1 and retard the migration of suppressor cells.

Key Points: 
  • MOR210/TJ210 is thought to block the interaction between C5a and C5aR1 by binding to C5aR1 and retard the migration of suppressor cells.
  • "The FDA clearance of the IND application to initiate a Phase 1 clinical trial of MOR210/TJ210 is an important step forward in developing a new treatment for patients with advanced cancer", said Dr Malte Peters, Chief Research & Development Officer of MorphoSys.
  • MorphoSys and I-Mab entered into an exclusive strategic collaboration and licensing agreement to develop and commercialize MOR210/TJ210 in November 2018.
  • Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees.

ChemoCentryx to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, March 10, 2020

Retrieved on: 
Tuesday, March 3, 2020
C5a receptor, Complement component 5a, C5a, Complement system, Complement component 5

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International).

Key Points: 
  • To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International).
  • A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com .
  • The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
  • Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.

ChemoCentryx to Present at Two Upcoming Investor Conferences

Retrieved on: 
Thursday, August 29, 2019
Branches of biology, Medical specialties, Medicine, Rheumatology, Vasculitis, Complement component 5a, C5a receptor, ANCA, Medication, C5a, Neutrophil, Complement system

A replay of the webcast will be available on the Company's website for two weeks following the live presentation.

Key Points: 
  • A replay of the webcast will be available on the Company's website for two weeks following the live presentation.
  • Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.
  • Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA-associated Vasculitis).
  • Avacopan was also granted access to theEuropean Medicines Agency's(EMA) PRIority MEdicines (PRIME) initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need.

ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorisation (CMA) Application for ANCA-Associated Vasculitis in Europe, Phase III Advocate Trial Data Release Planned for Q4 2019

Retrieved on: 
Thursday, January 24, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Research, Science, Branches of biology, Medical specialties, Organ systems, Rheumatology, Vasculitis, Complement component 5a, C5a receptor, ANCA, C5a, Vifor Pharma, Neutrophil, Complement system

Stefan Schulze, President of the Executive Committee and Chief Operating Officer of Vifor Pharma Group, commented, We strongly support the decision to focus on a full Market Authorisation.

Key Points: 
  • Stefan Schulze, President of the Executive Committee and Chief Operating Officer of Vifor Pharma Group, commented, We strongly support the decision to focus on a full Market Authorisation.
  • Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.
  • Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA-associated vasculitis).
  • This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.